03:31 AM EDT, 10/12/2026 (MT Newswires) -- Biopharmaceutical group Camurus (CAMX.ST) secured Health Canada's approval for Oczyesa as a maintenance treatment for adult patients with acromegaly who have responded to and tolerated somatostatin analog therapy. The approval is supported by the Acroinnova 1 and Acroinnova 2 phase 3 trials, with the first showing that a significantly higher proportion of patients treated with Oczyesa achieved normalized IGF-1 levels, compared with placebo, according to a Monday release. Meanwhile, the second trial demonstrated sustained IGF-1 normalization, reduced symptoms, and improved quality of life over 52 weeks of treatment. Oczyesa previously received marketing authorization in the European Union, the UK, and Australia.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.